Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies the side effects and best dose of radiation therapy in patients with brain tumors that have come back after previous treatment with radiation therapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in different ways may kill more tumor cells.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To estimate the rate of grade 3 or higher central nervous system (CNS) necrosis 6 months after reirradiation of the brain for recurrent tumor. SECONDARY OBJECTIVES: I. To evaluate acute and late toxicities of reirradiation. II. To evaluate longitudinal changes in symptom burden of patients undergoing reirradiation. III. To use Advanced Brain Tumor Imaging (ABTI) to evaluate changes in the brain after reirradiation, including progression, pseudoprogression, and radionecrosis. IV. To estimate progression-free survival (PFS) and overall survival (OS) following reirradiation. OUTLINE: Patients are assigned to 1 of 2 arms based on age. ARM I (Age 0-18 years): Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. ARM II (Age > 18 years): Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month, then every 2 months for 1 year, then every 3 months for 1 year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02698254
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date July 20, 2016
Completion date July 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Completed NCT03071913 - Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
Active, not recruiting NCT02389309 - Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors Phase 1
Active, not recruiting NCT02323880 - Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Phase 1
Completed NCT02167204 - 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors N/A
Completed NCT02575027 - Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A
Recruiting NCT02359565 - Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Phase 1
Completed NCT01609790 - Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Phase 2
Completed NCT02661282 - Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Phase 1/Phase 2
Recruiting NCT02754544 - Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors N/A
Completed NCT01904123 - STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain Phase 1
Active, not recruiting NCT02020720 - 18F-DOPA-PET in Planning Surgery in Patients With Gliomas Early Phase 1
Active, not recruiting NCT01503086 - Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy N/A
Active, not recruiting NCT02671981 - Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Phase 2
Recruiting NCT04588246 - Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery Phase 3
Completed NCT02658981 - Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Phase 1
Withdrawn NCT02521090 - EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma Phase 1/Phase 2